- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 4, 2023Robins Kaplan LLP Announces 2024 Partners
-
November 30, 2023U.S. Court of Appeals Affirms PTAB Decision in Favor of Robins Kaplan Client Collegium
-
November 20, 2023Kellie Lerner Named Interim Co-Lead Class Counsel in Taser And Body Camera Antitrust Litigation
-
December 12, 2023Ethics Check-In! – USPTO Insight and Practical Implications of AI
-
January 4, 2024 | January 9, 2024 | January 11, 2024Payment Card Settlement for U.S. Merchants
-
Fall 2023All Is Not Lost: Personal Jurisdiction in a Post-BMS World
-
November 10, 2023E-Commerce Platform Liability for Trademark Infringement
-
November 8, 2023Generative Artificial Intelligence, LLMs, And Fair Use After Warhol: The Copyright Office and Accountability
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Update: Investigation into Mirapex and its Link With Compulsive Gambling Disorders
March 17, 2006
Robins, Kaplan, Miller & Ciresi L.L.P. has filed lawsuits on behalf of clients who developed a compulsive gambling disorder while on Mirapex.
According to a study by Mayo Clinic doctors released in July 2005, the drug Mirapex may cause compulsive gambling addictions.1 The Mayo study builds upon earlier research which suggested a link between dopamine agonist drugs, like Mirapex, and a range of compulsive behaviors, such as compulsive gambling. For example, a study published in 2003 by researchers at the Muhammad Ali Parkinson Research Center at the Barrow Neurological Institute in Arizona found increased pathological gambling in those being treated with high-dose dopamine agonist therapy, and in particular with Mirapex.2 The lead author of the Mayo Clinic study has explained that when a patient develops the Mirapex side effects of compulsive behaviors but then stops using Mirapex, the results are very dramatic "like a light switch being turned off when they stopped the drug."3
Mirapex and Parkinson's Disease
Mirapex, which is also known as pramipexole, is prescribed to treat symptoms of Parkinson's Disease and other movement disorders like Restless Legs Syndrome. It is also being studied for the treatment of fibromyalgia. As a dopamine agonist, Mirapex stimulates nerves in the brain which are normally stimulated by dopamine, a brain chemical that helps control motor functions and movement. The areas of the brain and the dopamine receptors that Mirapex stimulates, particularly within the brain's mesolimbic pathway, are the areas associated with addictive behaviors.
Mirapex is manufactured and distributed by Boehringer Ingelheim Pharmaceuticals, a company headquartered in Germany, and by Pfizer Pharmaceuticals, headquartered in New York. Mirapex is the most commonly prescribed drug in its class.
[1] M. Leann Dodd, M.D, Kevin J. Klos, MD, James H. Bower, MD, Yonas E. Geda, MD, Keith A. Josephs, MST, MD, J. Eric Ahlskog, PhD, MD, Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease, Archives of Neurology, Vol. 62, Sept. 2005.
[2] E. Driver-Dunckley, MD, J. Samanta, MD, M. Stacy, MD, Pathological Gambling Associated With Dopamine Agonist Therapy in Parkinson's Disease, Neurology, Vol. 61, August 2003.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Kate E. Jaycox
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.